The EPS miss is notable but the core commercial story remains strong with 31% QoQ revenue growth and increasing profitability. The primary risk is the United Therapeutics patent litigation seeking injunctive relief — any adverse ruling could severely impact YUTREPIA's market access. Monitor the upcoming court decisions and the Re-Spire L606 trial enrollment progress.
Price Chart
Executive Summary
Liquidia reported Q2 2026 net product sales of $170.4M (+31% QoQ), net income of $74.7M ($0.74 diluted EPS), and adjusted EBITDA of $96.3M. While EPS of $0.74 missed consensus estimates of $0.84, the company delivered its fourth consecutive quarter of increasing profitability with strong cash generation ($284.2M ending cash, up $61.4M QoQ). The ongoing patent litigation with United Therapeutics seeking injunctive relief remains a key overhang on the stock.
Key Financial Metrics
Key Facts
- Q2 2026 YUTREPIA net product sales of $170.4M, up 31% QoQ from Q1 2026
- GAAP diluted EPS of $0.74 missed consensus estimate of $0.84 (-11.5% miss)
- Net income of $74.7M, fourth consecutive quarter of increasing profitability
- Adjusted EBITDA of $96.3M; cash and equivalents of $284.2M, up $61.4M QoQ
- Over 5,000 patients started on YUTREPIA since launch; ~5,900 unique patient prescriptions
- Ongoing patent litigation with United Therapeutics seeking injunctive relief that could block YUTREPIA sales
Financial Impact
EPS miss of -11.5% vs consensus ($0.74 actual vs $0.84 estimate) on revenue of $171.7M total revenue ($170.4M product sales)
Risk Factors
- United Therapeutics patent litigation seeking injunctive relief could block YUTREPIA sales for PAH and/or PH-ILD
- EPS miss of -11.5% vs consensus may pressure near-term sentiment
- R&D expenses increased 185% YoY to $17.2M driven by L606 program costs
- SG&A expenses increased 48% YoY to $57.4M as commercial infrastructure scales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343472 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $42.65 (+25.66%) |
Oct 13, 2026 13d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $42.65 (+25.66%) |
Sep 30, 2026 26d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $42.65 (−52.38%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $42.65 (−37.86%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $42.65 (−37.86%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $42.65 (−40.23%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $42.65 (−39.31%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $42.65 (−45.87%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $42.65 (+45.87%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $42.65 (−50.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers